Pfizer 2006 Annual Report Download - page 78

Download and view the complete annual report

Please find page 78 of the 2006 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

2006 Financial Report 77
Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc and Subsidiary Companies
QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH
2005
Revenues $12,143 $11,452 $11,263 $12,547
Costs and expenses 9,191 8,016 7,558 8,832
Acquisition-related in-process research and development charges 2 260 1,390 —
Restructuring charges and acquisition-related costs 216 264 303 573
Income from continuing operations before provision for taxes
on income, and minority interests 2,734 2,912 2,012 3,142
Provision/(benefit) for taxes on income 2,576 (464) 530 536
Minority interests 2136
Income from continuing operations 156 3,375 1,479 2,600
Discontinued operations:
Income from discontinued operations—net of tax 104 88 107 152
Gains on sales of discontinued operations—net of tax 41 — 3 3
Discontinued operations—net of tax 145 88 110 155
Cumulative effect of a change in accounting principles — — — (23)
Net income $ 301 $ 3,463 $ 1,589 $ 2,732
Earnings per common share—basic:
Income from continuing operations $ 0.02 $ 0.46 $ 0.20 $ 0.35
Discontinued operations—net of tax 0.02 0.01 0.02 0.02
Cumulative effect of a change in accounting principles ————
Net income $ 0.04 $ 0.47 $ 0.22 $ 0.37
Earnings per common share—diluted:
Income from continuing operations $ 0.02 $ 0.46 $ 0.20 $ 0.35
Discontinued operations—net of tax 0.02 0.01 0.02 0.02
Cumulative effect of a change in accounting principles ————
Net income $ 0.04 $ 0.47 $ 0.22 $ 0.37
Cash dividends paid per common share $ 0.19 $ 0.19 $ 0.19 $ 0.19
Stock prices
High $ 27.75 $ 29.21 $ 27.82 $ 25.57
Low $ 23.80 $ 25.52 $ 24.67 $ 20.27
Basic and diluted EPS are computed independently for each of the
periods presented. Accordingly, the sum of the quarterly EPS
amounts may not agree to the total for the year.
All financial information reflects the following as discontinued
operations: Consumer Healthcare and certain European generics
businesses (see Note 3. Discontinued Operations).
Acquisition-related in-process research and development charges
primarily includes amounts incurred in connection with our
acquisitions of Vicuron and Idun (see Note 2. Acquisitions).
Restructuring charges and acquisition-related costs include
integration and restructuring charges primarily related to our
acquisition of Pharmacia (see Note 5. Acquisition-Related Costs)
and the restructuring charges related to our AtS productivity
initiative (see Note 4. Adapting to Scale Productivity Initiative).